Chemistry:MK-4409
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C22H17FN3O2S |
| Molar mass | 406.46 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
MK-4409 is an experimental drug which acts as a potent and selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), with an IC50 of 11 nM, and both analgesic and antiinflammatory effects in animal studies. It was studied for the treatment of neuropathic pain and progressed to early stage human clinical trials by 2009.[1][2]
See also
- LY-2183240
- URB-597
- PF-3845
- BIA 10-2474
References
- ↑ "Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain". ACS Medicinal Chemistry Letters 5 (6): 717–21. June 2014. doi:10.1021/ml5001239. PMID 24944750.
- ↑ Merck (15 October 2009). "Merck Pipeline, Oct 2009". Merck. https://www.merck.com/research/pipeline/MerckPipeline_Oct09_Final_10-15-09_10-Q.pdf.
External links
- "MK 4409". Adis Insight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800031105.
 |  |
